Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2015
This article has no abstract
Epistemonikos ID: de01b94ba5de8d9f4eabdfe958deba9593a708dd
First added on: Feb 07, 2025